NCT01764828View on ClinicalTrials.gov

BAY86-9766 Plus Gemcitabine Phase I Study in Asian

PHASE1CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

February 5, 2013

Primary Completion Date

December 18, 2014

Study Completion Date

February 10, 2015

Conditions
Neoplasms
Interventions
DRUG

Refametinib (BAY86-9766)

DRUG

Gemcitabine

Trial Locations (3)

200032

Shanghai

277-8577

Kashiwa

03080

Seoul

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT01764828 - BAY86-9766 Plus Gemcitabine Phase I Study in Asian | Biotech Hunter | Biotech Hunter